Galmed Pharmaceuticals Ltd (GLMD) Shares Sold by Millennium Management LLC

Millennium Management LLC trimmed its holdings in shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) by 93.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,706 shares of the biopharmaceutical company’s stock after selling 309,397 shares during the period. Millennium Management LLC’s holdings in Galmed Pharmaceuticals were worth $141,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Premier Asset Management LLC bought a new position in shares of Galmed Pharmaceuticals during the 4th quarter worth approximately $505,000. Wells Fargo & Company MN bought a new position in shares of Galmed Pharmaceuticals during the 3rd quarter worth approximately $297,000. Raymond James & Associates boosted its holdings in shares of Galmed Pharmaceuticals by 19.0% during the 4th quarter. Raymond James & Associates now owns 86,201 shares of the biopharmaceutical company’s stock worth $589,000 after buying an additional 13,764 shares in the last quarter. First Midwest Bank Trust Division boosted its holdings in shares of Galmed Pharmaceuticals by 802.4% during the 4th quarter. First Midwest Bank Trust Division now owns 214,872 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 191,061 shares in the last quarter. Finally, ETF Managers Group LLC boosted its holdings in shares of Galmed Pharmaceuticals by 48.9% during the 4th quarter. ETF Managers Group LLC now owns 34,656 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 11,382 shares in the last quarter. Hedge funds and other institutional investors own 36.62% of the company’s stock.

Shares of NASDAQ:GLMD opened at $6.92 on Thursday. The company has a current ratio of 36.11, a quick ratio of 36.11 and a debt-to-equity ratio of 0.01. Galmed Pharmaceuticals Ltd has a twelve month low of $5.58 and a twelve month high of $27.06. The company has a market cap of $145.46 million, a PE ratio of -12.81 and a beta of 2.59.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. Galmed Pharmaceuticals had a negative return on equity of 12.23% and a negative net margin of 423.62%. Equities analysts predict that Galmed Pharmaceuticals Ltd will post -1.14 EPS for the current fiscal year.

A number of research firms have issued reports on GLMD. Zacks Investment Research cut Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. ValuEngine cut Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Maxim Group restated a “buy” rating and set a $20.00 price target on shares of Galmed Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Galmed Pharmaceuticals in a report on Wednesday, May 8th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Galmed Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $32.78.

TRADEMARK VIOLATION WARNING: “Galmed Pharmaceuticals Ltd (GLMD) Shares Sold by Millennium Management LLC” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2019/05/16/galmed-pharmaceuticals-ltd-glmd-shares-sold-by-millennium-management-llc.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Featured Story: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding GLMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD).

Institutional Ownership by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.